Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval
China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...
China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...
Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) reported its Q3 2022 financial results,...
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing...
China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...
The College of Pharmacy at Nankai University has established a postgraduate practice base at the...
China-based Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, and compatriot firm WZ...
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced receiving multiple marketing approvals...
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has completed...
China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio...
China-based Ascletis Pharma Inc. (HKG: 1672) announced the submission of an Investigational New Drug (IND)...
China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the US...
Ping An Life Insurance Company of China Ltd released its 2022 Q3 financial report, showing...
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...
AccuMedical Beijing Ltd has secured approval from China’s National Medical Products Administration (NMPA) for its...
China-based InxMed (Nanjing) Co., Ltd has entered into a strategic partnership with Shanghai Huaota Biopharmaceutical...
China-based LEPU ScienTech Medical Technology (Shanghai) Co., Ltd is gearing up for an initial public...
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its Q3 2022 financial...
Shanghai-based tumor immunotherapy specialist OriginCell Therapeutics has announced that its investigational autologous chimeric antigen receptor...
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported a 4% year-on-year (YOY) increase in global...